TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04988802

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal Nutrients Solgar
Description: Patients will take dietary supplement Prenatal Nutrients from Solgar

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules based on starch.
Study: NCT04888091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton swab
Description: Removal of the cervical mucus with a cotton swab before embryo transfer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cannula
Description: Removal of the cervical mucus with a cannula before embryo transfer.
Study: NCT06325566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rexlemestrocel-L + HA mixture
Description: Rexlemestrocel-L will be combined in 1:1 by-volume ratio with HA solution and the resulting mixture will be administered as intradiscal injection.
Study: NCT05343416

Intervention type: PROCEDURE
Intervention: Open abdomen procedure
Description: All patients underwent to open abdomen procedure
Study: NCT06325566

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline solution injection adjacent to the index disc.
Study: NCT05483283

Intervention type: OTHER
Group type: OTHER
Intervention: Empowerment and Navigation
Description: Empowerment and Navigation

Intervention type: OTHER
Group type: OTHER
Intervention: SOC
Description: SOC
Study: NCT06258018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodal
Description: given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days
Study: NCT06338709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BariClip® Device Treatment
Description: Device Administration (Implantation)
Study: NCT05863507

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape powder supplementation
Description: The participants will be willing to consume the grape powder dissolve in water daily for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will be willing to consume the placebo powder, similar to the grape powder, dissolve in water daily for 6 weeks
Study: NCT05557643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the issues that arise in this participant population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: Mindfulness-Based Stress Reduction (MBSR) is a well-established evidence-based mindfulness training program initially developed by Jon Kabat-Zinn that has been shown to reduce symptoms of depression, anxiety, and burnout. The 8-week MBSR curriculum provides training in formal meditation practices including body scan techniques, mindfulness meditation, and yoga. Mindfulness can be understood as the non-judgmental acceptance and investigation of present experience, including body sensations, internal mental states, thoughts, emotions, impulses and memories, in order to reduce suffering or distress and to increase well-being.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: Mindfulness-Based Stress Reduction (MBSR) is a well-established evidence-based mindfulness training program initially developed by Jon Kabat-Zinn that has been shown to reduce symptoms of depression, anxiety, and burnout. The 8-week MBSR curriculum provides training in formal meditation practices including body scan techniques, mindfulness meditation, and yoga. Mindfulness can be understood as the non-judgmental acceptance and investigation of present experience, including body sensations, internal mental states, thoughts, emotions, impulses and memories, in order to reduce suffering or distress and to increase well-being.
Study: NCT06023446

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography
Description: The retina is imaged using infrared light. Images collected in light are compared to those collected in darkness to extract information about function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography
Description: The retina is imaged using infrared light. Images collected in light are compared to those collected in darkness to extract information about function.
Study: NCT04505072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PR-ESSENCE
Description: Manual-based training of mutual problem-solving

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: General support in daily structure and activities that is given to all youth staying at the treatment homes
Study: NCT06100263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized exercise program
Description: guided exercise program for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: American Cancer Society Physical Activity and the Person with Cancer summary for patients will be provided
Study: NCT05787496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC525
Description: Monoclonal antibody specific for LAIR-1
Study: NCT05051553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Specified dose on specified days
Study: NCT05929768

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT04881955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Ecopipam
Description: \[14C\]-Ecopipam
Study: NCT05403411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distance education for nursing students on critical thinking
Description: The students in the intervention group were trained with distance education method for the first 4 weeks, and in the following weeks, with theoretical and case presentations. Critical thinking techniques were used during the trainings. A total of 8 weeks of training was given. Training was given for the first 5 weeks without interruption, and for the next three weeks with a two-week break. Critical thinking disposition scale was applied in the pre-test and post-test.
Study: NCT05929768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT04990622

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich diet
Description: Inclusion of foods rich in flavonoids.
Study: NCT04053842

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: PET imaging uses small amounts of a radioactive substance called a tracer to look for disease in the body. The radioactive substance used in this study is \[18F\]PSMA-1007.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-1007 Injection
Description: \[18F\]PSMA-1007 is given by intravenous (IV) injection into the arm. It travels through the blood stream where it is rapidly taken up by prostate cancer cells and emits tiny, positively charged particles (called positrons) that produce signals into the body. These signals are detected by the PET component of the PET/MRI scanner.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sodium MRI
Description: Sodium MRI uses magnetic waves and a specially-designed rectal probe to measure the sodium concentration (amount of salt) in the prostate. Previous research has shown that higher sodium concentrations in the prostate might be a sign of more aggressive cancer.
Study: NCT04053842

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI
Description: MRI is a common medical diagnostic tool that uses magnetic waves and a contrast agent (dye) called Gadovist to take pictures of body tissue.
Study: NCT05986877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1201 Subcutaneous injection
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1201 Subcutaneous injection
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1201 Subcutaneous injection
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1201 Subcutaneous injection
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT06479304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Oral Tablet
Description: Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet
Description: Prednisone is given at the dose of 1mg/kg every morning after meals for 2 weeks ( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, prednisone will be given at the dose for 2 more weeks ), then tapering off.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone tablet
Description: Prednisone is given at the dose of 1mg/kg every morning after meals for 2 weeks ( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, prednisone will be given at the dose for 2 more weeks ), then tapering off.
Study: NCT04782830

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: A uniaxial accelerometer-based activity monitor (ActivpalTM) will be worn by participants on one of the thighs during the 7 days of the placebo and treatment periods.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: A uniaxial accelerometer-based activity monitor (ActivpalTM) will be worn by participants on one of the thighs during the 7 days of the placebo and treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo pill
Description: Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine or atomoxetine pill
Description: Either midodrine or atomoxetine at their regular dose.
Study: NCT06258018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodal
Description: given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodal
Description: given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days
Study: NCT05287984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
Description: Patients aged 65 years or younger who can tolerate FCR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, bendamustine, rituximab
Description: For patients older than 65 years or who cannot tolerate FCR regimens.
Study: NCT06258018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodal
Description: given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodal
Description: given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: given orally in continous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: given orally in continous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: given orally in continous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: given orally in continous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: given orally in continous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: given orally in continous
Study: NCT06150781

Intervention type: DRUG
Intervention: erenumab-aooe
Description: Dose and treatment duration will be advised by the HCP
Study: NCT05485792

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FAPI PET/CT and 18F-FDG PET/CT
Description: Each subject undergo both 18F-FDG and 68Ga-FAPI PET/CT scans within 1 week
Study: NCT06496217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 2109
Description: Group 1: Subjects with mild renal impairment (eGFR ≥ 60 and \< 90 mL/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 2109
Description: Group 2: Subjects with moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 2109
Description: Group 3: Subjects with severe renal impairment (eGFR \< 30 mL/min), or kidney failure and not receiving dialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 2109
Description: Group 4: Matched healthy subjects with normal renal function (eGFR ≥ 90 mL/min)
Study: NCT06188793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality-directed BGBT
Description: Enrolled participants will receive up to 3-days of VR-directed BGBT through several modules including distraction games, mindfulness meditation, breathing exercises, and cognitive behavioral therapy based coaching. Participants will complete questionnaires at various time points and be asked to complete a semi-structured interview post-intervention.
Study: NCT06580431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva and serum sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Saliva and serum were then stored at -80 °C until analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva and serum sampling
Description: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Saliva and serum were then stored at -80 °C until analysis.
Study: NCT04928105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Senl-T7
Description: Patients will be treated with CD7 CAR-T cells
Study: NCT03266770

Intervention type: DEVICE
Group type: OTHER
Intervention: RELIEF Stent
Description: The RELIEF stent will be placed under cystoscopy. The stent with pusher will be placed over the guidewire and inserted. The pusher will be positioned, the guidewire will be removed, and the pusher will be retracted. The position of the stent will be confirmed by x-ray (C-arm).
Study: NCT05435274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10376
Description: HS-10376 will be administered orally once daily in a continuous regimen
Study: NCT05929768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study: NCT05205902

Intervention type: OTHER
Group type: OTHER
Intervention: Low-dose total-skin electron-beam therapy
Description: Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.

Intervention type: OTHER
Group type: OTHER
Intervention: Phototherapy
Description: Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first.~Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy.
Study: NCT06387290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Oriented Recovery Enhancement
Description: Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative therapeutic approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Centered Chronic Pain Management Visits
Description: Participant will meet with their primary care provider for patient-centered care and shared decision making while discussing their chronic pain management strategy (e.g., opioid analgesics).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Centered Chronic Pain Management Visits
Description: Participant will meet with their primary care provider for patient-centered care and shared decision making while discussing their chronic pain management strategy (e.g., opioid analgesics).
Study: NCT04805255

Intervention type: RADIATION
Intervention: Hypofractionated Stereotactic Radiotherapy
Description: A course of hypofractionated stereotactic radiotherapy (HF-SRT) is delivered within 2 weeks with a cumulative dose of 3000 - 3500 cGy in 5 fractions.
Study: NCT06252103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Gluconate 300 MG
Description: iron salt one tab 300 mg contain 35 mg of elemental iron given 2 doses 600 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous gluconate with lactoferrin
Description: Lactoferrin is a glycoprotein from the transferrin family consist of 691 amino acids,Lactoferrin is a protein found in cow milk and human milk
Study: NCT05782257

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Supplementation
Description: Take one 25mg Zn gluconate tablet daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zn-Optimized Diet
Description: Consume 11 mg/day of zinc-rich foods for females and 14 mg/day in males.
Study: NCT05929768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study: NCT06078007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyMoodCoach
Description: The MyMoodCoach prevention intervention is an evidence-based online intervention based on cognitive-behavioral therapy principles such as behavioral activation, problem solving and challenging negative thoughts.
Study: NCT05334485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: Oral 60mg pyridostigmine bromide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral starch placebo
Study: NCT06546020

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Haskap berry smoothie
Description: A smoothie blend of berries and water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Haskap berry smoothie
Description: A smoothie blend of berries and water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: A smoothie with no polyphenolic content and matched in carbohydrate composition to the experimental haskap smoothie

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: A smoothie with no polyphenolic content and matched in carbohydrate composition to the experimental haskap smoothie
Study: NCT06483620

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropathy - and Foot Ulcer - Specific Quality of Life instrument (Neuro Qol)
Description: The NeuroQoL questionnaire is a valid, reliable, and self-reported questionnaire. It has 35-items with six domains namely, painful symptoms and paresthesia (items 1-7), reduction or loss of ability to feel (items 8-10), unsteadiness while walking/standing/diffuse sensory-motor symptoms (items 11-13), limitation in daily living (items 14 - 16), interpersonal problems (items 17-20), emotional distress (items 21- 27) and end with an overall assessment of quality of life or satisfaction with experiences in the above six domains \[1 item in each domains, i.e. additional 6 items (items 28-33)\]. The two final items (items 34-35) assess overall impact of neuropathy on QoL \[5\]. The scoring of the questionnaire is according to a five-point Likert scale, all the time, most of the time, some of the time, occasionally, never. Each domain has a maximum score 5 and minimum 1, where 5 means that the QoL is affected all the time because of the foot problem while 1 means never it affects their QoL
Study: NCT05381103

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-PET and SOC MRI
Description: 60 min continuous acquisition of PET data after 3-6 mCI injection of \[68Ga\]P16-093 followed by contrast-CT

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SOC MRI
Description: Standard of care MRI